肝癌术后门静脉植入泵化疗的临床效果

摘要

目的 探讨肝癌患者手术切除术后门静脉植入泵化疗的临床治疗效果.方法 收集原发性肝癌患者100例,随机分为常规手术组(对照组,n=50)和常规手术+门静脉植入泵化疗组(化疗组,n=50).对照2组的复发率和生存率.结果 对照组术后6个月、1年、3年、5年的复发率分别为12.0%、56.0%、72.1%、100.0%,化疗组的复发率分别为4.0%、30.0%、58.0%、76.0%,2组之间具有统计学差异(P<0.05).对照组术后6个月、1年、3年、5年的生存率分别为92.0%、48.0%、18.0%、0%,化疗组的生存率分别为94.0%、58.0%、32.0%、8.0%,2组术后6个月和1年生存率差异无统计学意义(P>0.05),但3年和5年时2组的生存率差异有统计学意义(P<0.05).结论 肝癌术后门静脉植入泵化疗操作简单,临床疗效显著,值得推广应用.%Objective To estimate the clinic effects of portal vein infusion drug deliver system(PVIDDS)on recurrence of hepatocellular carcinoma in patterns after hepatectomy.Methods A total of 100 hepatocellular carcinoma patterns with hepa-tectomy were enrolled in this study.The patients were randomly devided into 2 groups:normal treatment group(control group,n=50)and PVIDDS group(chemotherapy group,n=50).The recurrence and survival rates were compared between the 2 groups. Results 6-month,1-year,3-year,and 5-year recurrence rates were 12.0%,56.0%,72.1% and 100.0% in the control group, and 4.0%,30.0%,58.0%,and 76.0% in chemotherapy group,respectively.There was significant difference between the 2 groups(P<0.05).6-month,1-year,3-year,and 5-year survival rates were 92.0%,52.2%,18.0%,0%in the control group,and 94.0%,58.0%,32.0%,8.0%in chemotherapy group.The 6-month and 1-year survival rates had no significant difference be-tween the 2 groups(P>0.05).However,3-year and 5-year survival rates in chemotherapy group were higher than that of the con -trol group(P<0.05).Conclusion PVIDDS can effectively treated hepatocellular carcinoma patients after hepatectomy,and it is worthy of clinical application.